Monitor trading volume and price action for signs of Lincoln Park selling into the market. The company's reliance on equity line financing and going concern status suggests continued dilution risk. Watch for any clinical trial catalysts that could offset the overhang.
Price Chart
Executive Summary
The SEC declared effective Acurx Pharmaceuticals' S-1 registration statement (File No. 333-298801) on September 17, 2026. This allows Lincoln Park Capital Fund, LLC to resell up to 1,500,000 shares of common stock under an existing Purchase Agreement. The company receives no proceeds from the resale but may receive up to $2.8 million in additional gross proceeds from future direct sales to Lincoln Park, adding to the $9.2 million already received. The effectiveness adds near-term dilution overhang as Lincoln Park can sell into the market at any time.
Key Facts
- Effectiveness date: September 17, 2026
- Registration covers up to 1,500,000 shares of common stock for resale by Lincoln Park Capital Fund, LLC
- Company has already received $9.2 million from prior sales to Lincoln Park under the Purchase Agreement
- Company may receive up to an additional $2.8 million from future sales to Lincoln Park
- Stock closed at $1.42 per share on September 4, 2026
- Company is pre-revenue with a going concern opinion from its auditor per prior filings
Financial Impact
Up to 1.5M shares of potential resale dilution; company may receive up to $2.8M additional gross proceeds from Lincoln Park
Risk Factors
- Immediate dilution risk as Lincoln Park can resell shares at any time
- Company has a going concern opinion, indicating significant financial risk
- Pre-revenue biotech with no approved products or revenue stream
- Stock price may face downward pressure from continuous selling by Lincoln Park
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-003000 |
| Document: 9999999995-26-003000-index.html | 9999999995-26-003000 |
| Document: 9999999995-26-003000.txt | 9999999995-26-003000 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 18, 2026 5w ago | EFFECT | $1.39 $1.10 | ▲ +20.86% | ▲ +21.07% | $1.07 (+23.02%) |
Aug 14, 2026 10w ago | Press Release | $1.40 $1.39 | ▼ −0.36% | ▲ +1.63% | $1.07 (−23.30%) |
May 4, 2026 25w ago | S-1 | $2.00 $1.80 | ▲ +10.00% | ▲ +14.95% | $1.07 (+46.50%) |
May 4, 2026 25w ago | S-1 | $2.00 $1.80 | ▲ +10.00% | ▲ +14.95% | $1.07 (+46.50%) |
Apr 16, 2026 27w ago | 8-K | $2.49 $1.99 | ▼ −20.08% | ▼ −25.90% | $1.07 (−57.03%) |
Apr 16, 2026 27w ago | 424B5 | $2.49 $1.99 | ▲ +20.08% | ▲ +25.90% | $1.07 (+57.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers